<DOC>
	<DOCNO>NCT00964548</DOCNO>
	<brief_summary>Subarachnoid hemorrhage ( SAH ) devastate acute brain injury due bleed onto brain surface rupture aneurysm . Cerebral vasospasm ( cVSP ; critical narrowing brain artery ) know complication SAH significantly increase disability death SAH . Vasospasm difficult treat lead stroke . Animal study show muscle artery wall play role cVSP . Dantrolene FDA approve extensively use clinical practice muscle relaxant 30 year . It show provide benefit animal study cVSP , well small number human . Therefore , plan undertake study evaluate safety tolerability treatment dantrolene patient cVSP SAH , determine maximal tolerate dose use future study determine treatment Dantrolene improve outcome patient cVSP SAH .</brief_summary>
	<brief_title>Safety Study Dantrolene Treat Cerebral Vasospasm After Subarachnoid Hemorrhage</brief_title>
	<detailed_description>Our main objective : 1 ) evaluate safety tolerability vary dos dantrolene , determine treatment related adverse event , participant cVSP SAH ; 2 ) determine maximal tolerate dose adopt subsequent study 3 ) determine efficacy trend dantrolene brain vessel assess ultrasound brain vessel ( transcranial Doppler ) . We hypothesize dantrolene well-tolerated minimal serious adverse effect patient cVSP SAH . The result potentially bring new treatment patient SAH . cVPS SAH frequent cause disability death . A successful study demonstrate safety dantrolene would considerable public health significance .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Vasospasm , Intracranial</mesh_term>
	<mesh_term>Dantrolene</mesh_term>
	<criteria>Participants aneurysmal SAH admit Massachusetts General Hospital NeuroICU ( Blake 12 ) undergo standardofcare daily transcranial doppler ( TCD ) . Participants unilateral bilateral anterior cerebral artery ( ACA ) , middle cerebral artery ( MCA ) , posterior cerebral artery ( PCA ) , basilar artery vasospasm define follow TCD criterion &gt; 50 % mean velocity increase baseline mean TCD velocity ( baseline first TCD measurement , usually within 24hrs admission ) , peak systolic TCD velocity 200 cm/s high MCA ACA ( MCA concurrent ipsilateral LR 3.0 high ) , peak systolic TCD velocity 120 cm/s high PCA basilar artery , daily 100 cm/s peak systolic TCD velocity increase previous day , longitudinal mean TCD velocity increase 80 cm/s Inability obtain consent patient health care proxy Age &lt; 18 year Pregnancy Traumatic SAH Known allergy dantrolene Prior history cirrhosis hepatitis B/C , two follow three liver enzymes elevate great : ALT &gt; 165 Units/L , AST &gt; 120 Units/L , alkaline phosphatase &gt; 345 Units/L ( three time upper limit normal ) Participants verapamil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>vasospasm</keyword>
	<keyword>subarachnoid hemorrhage</keyword>
	<keyword>neurocritical care</keyword>
	<keyword>dantrolene</keyword>
	<keyword>vasorelaxation</keyword>
</DOC>